Ascendis Pharma A/S (ASND) News Today

Ascendis Pharma A/S (NASDAQ: ASND) saw its shares rise today after a wave of upbeat earnings results, bullish pipeline updates, and multiple analyst price-target increases.

• Positive Sentiment: Q2 loss narrower than feared and revenue topped consensus estimates. Ascendis Pharma shares rise on narrower-than-feared Q2 loss, revenue beat
• Positive Sentiment: Technical momentum improved as the ADR’s Relative Strength rating jumped to 92. Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 92
• Positive Sentiment: Citigroup raised its price target from $243 to $290 and maintains a “buy” rating. Benzinga
• Positive Sentiment: Royal Bank of Canada boosted its target from $210 to $230 with an “outperform” rating. Benzinga
• Positive Sentiment: UBS inched its target up from $306 to $307 and keeps a “buy” call. Benzinga
• Positive Sentiment: Wedbush raised its target from $212 to $220, reiterating an “outperform” view. Benzinga
• Positive Sentiment: Cantor Fitzgerald lifted its target from $200 to $203 with an “overweight” rating. Benzinga
• Positive Sentiment: Stifel Nicolaus jumped its target from $212 to $254, keeping a “buy” recommendation. Benzinga
• Positive Sentiment: Reported Q2 EPS of ($0.93) vs. ($1.42) expected and revenue of $216.3 M vs. $163.2 M consensus, driven by strong YORVIPATH® and SKYTROFA® sales. View Press Release
• Positive Sentiment: FDA granted Priority Review for TransCon CNP (PDUFA Nov 30), SKYTROFA® approved for adult GHD label expansion, and COACH trial interim data were promising. Ascendis Pharma Reports Second Quarter 2025 Financial Results